Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GLAUKOS CORPORATION

(GKOS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
44.01(c) 43.03(c) 41.73(c) 41.59(c) 40.27(c) Last
374 984 394 307 471 354 521 494 471 163 Volume
-3.27% -2.23% -3.02% -0.34% -3.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 288 M - -
Net income 2021 -43,1 M - -
Net cash position 2021 177 M - -
P/E ratio 2021 -40,4x
Yield 2021 -
Sales 2022 268 M - -
Net income 2022 -72,4 M - -
Net cash position 2022 171 M - -
P/E ratio 2022 -23,1x
Yield 2022 -
Capitalization 1 887 M 1 887 M -
EV / Sales 2021 5,93x
EV / Sales 2022 6,40x
Nbr of Employees 653
Free-Float 96,1%
More Financials
Company
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that is focused on developing therapies for the treatment of glaucoma, corneal disorders, and retinal disease. The Company’s products are designed to treat mild-to-moderate open-angle glaucoma, the iStent, the iStent inject, and the iStent inject W. The Company’s Micro-Invasive Glaucoma Surgery (MIGS) serves as an alternative to... 
More about the company
Ratings of Glaukos Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about GLAUKOS CORPORATION
11/22GLAUKOS : Investor Presentation November 2021
PU
11/22GLAUKOS CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
11/19Glaukos Announces Participation in Upcoming Investor Conferences
BU
11/11Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Aca..
BU
11/09Berenberg Bank Adjusts Glaukos' Price Target to $60 From $65, Maintains Buy Rating
MT
11/08GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
11/05Jefferies Adjusts Price Target on Glaukos to $60 from $54, Keeps Hold Rating
MT
11/04GLAUKOS : Q3 Earnings Snapshot
AQ
11/04Glaukos Corporation Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/04Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Loss $-0.21, vs. Street Est of $-0.2..
MT
11/04Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q3 Revenue $74.7M, vs. Street Est of ..
MT
11/04GAAP to Non-GAAP Reconciliation Tables – Q3 2021
PU
11/04Glaukos Corporation Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/04Glaukos Corporation Announces Third Quarter 2021 Financial Results
BU
11/04Glaukos Corporation Provides Revenue Guidance for the Year 2021
CI
More news
News in other languages on GLAUKOS CORPORATION
11/04Earnings Flash (GKOS) GLAUKOS CORPORATION annonce un chiffre d'affaires de 74,7 million..
11/04Glaukos Corporation fournit des prévisions de revenus pour l'année 2021
08/05Earnings Flash (GKOS) GLAUKOS CORPORATION affiche un chiffre d'affaires de 78,1 million..
08/05Glaukos Corporation fournit des prévisions de ventes pour le troisième trimestre et l'e..
06/10Glaukos achève le recrutement des patients pour l'étude de phase avancée de l'iDose TR ..
More news
Analyst Recommendations on GLAUKOS CORPORATION
More recommendations
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | GKOS | US3773221029 | MarketScreener
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 40,27 $
Average target price 54,38 $
Spread / Average Target 35,0%
EPS Revisions
Managers and Directors
Thomas William Burns President, Chief Executive Officer & Director
Joseph E. Gilliam CFO, CAO & Senior VP-Corporate Development
William J. Link Chairman
L. Jay Katz Chief Medical Officer
Tomas Navratil Senior Vice President-Research & Development
Sector and Competitors